Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

Yasutaka Sukawa,Akitaka Makiyama,Taito Esaki,Gen Hirano,Masato Komoda,Tomomi Kashiwada,Junji Kawada,Ayumu Hosokawa,Takashi Tsuda,Akihito Tsuji,Toshikazu Moriwaki,Hiroaki Tanioka,Kimio Yonesaka,Kazuto Nishio,Katsuhiko Nosho,Kentaro Yamazaki,Shuichi Hironaka,Narikazu Boku,Ichinosuke Hyodo,Kei Muro

Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

2018

4029Background: WJOG7112G study, comparing paclitaxel plus trastuzumab (PT; n = 44) with paclitaxel alone (P; n = 45), did not demonstrate survival benefit of trastuzumab continuation beyond progre...

Keywords:

Refractory
Trastuzumab
Cancer
Oncology
Gastro-
Biomarker (medicine)
Pathology
Paclitaxel/trastuzumab
Internal medicine
Medicine
gastro esophageal junction
in patient
Paclitaxel
weekly paclitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations